OBJECTIVES: Mitral valve replacement using a bioprosthesis remains controversial in young patients because data on long-term outcomes are missing. This study evaluated the long-term results of the PERIMOUNT pericardial mitral bioprosthesis in patients aged 65 years or younger.
INTRODUCTION
The use of bioprostheses has increased considerably in the past decade and has led to a substantial reduction in mechanical valve implantations [1] . This trend may be explained by an increasing number of studies reporting improved long-term durability of more recent tissue valve models [2] [3] [4] . For mitral valve replacement (MVR), the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) guidelines recommend a bioprosthetic valve for patients aged >70 years (Class IIa), while both mechanical and bioprosthetic valves are considered acceptable for patients aged between 65 and 70 years [5] . According to the 2017 American College of Cardiology/American Heart Association (ACC/AHA) guidelines [6] , patient age is no longer a Class I recommendation. There is a Class IIa recommendation to use a mechanical valve in patients aged <50 years who do not have a contraindication to anticoagulation, a bioprosthetic valve in patients aged >70 years and either a bioprosthetic or a mechanical valve in patients aged between 50 and 70 years.
Nevertheless, biological MVR in young patients remains controversial, and the expected event rates for both perioperative and long-term valve-related complications have not been clearly determined.
The primary objective of this retrospective observational study was to report our 25-year experience with the CarpentierEdwards (CE) PERIMOUNT pericardial bioprosthesis (Edwards Lifesciences, Irvine, CA, USA) implanted in the mitral position in patients aged 65 years or younger.
PATIENTS AND METHODS
From 1984 to 2010, 148 CE PERIMOUNT pericardial bioprostheses were implanted during MVR in 148 patients aged 65 years or younger.
The choice of a bioprosthesis over a mechanical valve was based on the following criteria: patient's personal preference (n = 105), contraindications to oral anticoagulation (n = 2), anticipated reduced life expectancy due to other comorbidities (n = 20), replacement for endocarditis (n = 14) and planned pregnancy in the future (n = 7).
Patients undergoing multiple valve replacement were excluded from this analysis, but patients undergoing other concomitant surgeries were included. Table 1 presents baseline and perioperative characteristics. Operative techniques were described in detail previously [7] . Patients were operated on through a median sternotomy with standard cardiopulmonary bypass and moderate hypothermia (32-36 C). Myocardial protection was accomplished using crystalloid or blood cardioplegia and topical cooling. The surgical techniques remained constant throughout the entire experience: the bioprosthesis was rinsed in saline solution and secured with simple interrupted sutures. From 1988, the subvalvular apparatus of the posterior and anterior leaflets was preserved whenever possible.
Postoperative anticoagulation consisted of the low-molecularweight heparin enoxaparin, 4000 IU once daily until hospital discharge. Warfarin sodium was indicated only in cases of atrial fibrillation. Antiplatelet agents were used if there was a history of coronary artery disease or peripheral vascular disease.
Data were recorded prospectively. Systematically every year, questionnaires were mailed to all patients for clinical evaluation, and a transthoracic echocardiography was performed. If completed questionnaires were missing or adverse events occurred, phone calls and on-site visits were conducted. At the time of follow-up, the most recent echocardiographic data (<6 months) were included in our analysis. Social Security Death Index was used to confirm the date of death.
The closing interval for this study was 12 months. Morbidity and mortality were defined according to the current guidelines [8] .
The mitral bioprosthesis was considered deteriorated based on strict echographic assessment if severe regurgitation (effective regurgitant orifice area > _40 mm 2 ) and/or stenosis (mean transvalvular gradient above 8 mmHg) was observed, even if the patient was asymptomatic.
Because this study involved only retrospective chart review and used only de-identified data, it qualified for exemption from institutional review board approval.
Statistical analysis
Early events (< _30 days after surgery) were calculated as simple percentages (number of complications divided by number of patients). Linearized rates for late events (>30 days after surgery) represent the number of complications per 100 valve-years. The Kaplan-Meier actuarial analyses, including both early and late events, are presented with the Greenwood formula for variance. Survival curves were compared using the log-rank or MantelHaenszel test. Each patient's life expectancy was calculated using demographic life tables published by the French National Demographic Study Institute (INED) [9] and depends on patient age, year of surgery and gender. Life expectancy and expected valve durability were estimated by the median survival time (MST)-the time point at which the Kaplan-Meier curve crosses 0.5 probability-and the restricted mean-the area under the Kaplan-Meier curve, truncated with the latest available upper limit. Multivariate Cox proportional hazards regression was used to identify risk factors and estimate hazard ratios for the baseline hazards of mortality and valve deterioration. For non-fatal events such as structural valve deterioration (SVD), competing risk analyses [10] , often referred to in the literature as 'actual' analyses, were performed using the R cmprsk package (R software, version 2.13.1).
RESULTS
The mean follow-up was 8.6 ± 5.5 years, for a total of 1269 valveyears. Follow-up was complete for 99% (147 of 148) of patients. Three (2.0%) deaths were reported in the operative period. There were 51 late deaths for a linearized rate of 4.0% per valve-years. Of these, 16 (1.3% per valve-years) were designated as valve related: 2 thromboembolic events, 4 haemorrhages, 1 endocarditis, 1 SVD and 8 sudden deaths of unknown aetiology. At 10, 15 and 20 years, the overall actuarial survival rates averaged 70 ± 4%, 53 ± 6% and 31 ± 7%, respectively ( Fig. 1) .
A stepwise multivariate regression analysis, including 7 covariates [age, gender, concomitant procedures, atrial fibrillation, New York Heart Association (NYHA) functional class, valve size and aetiology], identified age at implantation (odds ratio 1.05, P = 0.026) and NYHA Class III-IV (odds ratio 2.81, P = 0.002) as significant risk factors affecting late survival. Thromboembolic events, bleeding and endocarditis. No cases of valve thrombosis were reported. Four thromboembolic events were reported for a linearized rate of 0.3% per valve-years, none within 30 days of operation. Two thromboembolic events led to death, 1 to permanent neurological deficit and the other was considered minor with complete recovery.
Valve-related complications
The 10-, 15-and 20-year rates of freedom from thromboembolism were 97 ± 2%, 93 ± 4% and 93 ± 4%, respectively.
Fifteen bleeding events were reported (linearized rate of 1.2% per valve-years) and led to death for 4 patients. Among them, 3 occurred within 30 days of operation, and 8 were related to the use of anticoagulants. At follow-up, 50% (22 of 44) of patients were anticoagulated with warfarin. Among them, 73% reported to have atrial fibrillation or atrial flutter. Twenty-year actuarial freedom from anticoagulant-related haemorrhage was 75 ± 12%.
Operated valve endocarditis was reported in 4 patients. One patient was reoperated, and 3 were successfully treated using antibiotics alone. Twenty-year actuarial freedom from endocarditis was 96 ± 2%.
Non-structural dysfunction. No clinically significant haemolysis was recorded in the absence of structural valve dysfunction.
Structural valve deterioration and reoperation for structural valve deterioration. SVD was reported in 47 (3.7% per valve-years) patients. Forty-four patients underwent reoperation, and 3 patients died rapidly after SVD was diagnosed. SVD was due to calcification in most cases (75%), followed by leaflet tear (23%) or both (2%). The mean time to SVD was 11.6 ± 4.3 years. No cases of SVD occurred within the first 5 years. The mean time to onset of SVD was significantly longer for valves with leaflet tear than those with calcification [14.6 years, 95% confidence interval (CI) 12.1-17.1 years and 10.5 years, 95% CI 9.2-11.7 years, respectively; P = 0.003].
At 10, 15 and 20 years, actuarial freedom from SVD was 78 ± 5%, 47 ± 7% and 19 ± 7%, respectively, and actuarial freedom from reoperation due to SVD was 82 ± 4%, 50 ± 6% and 25 ± 8%, respectively. The expected valve durability, calculated by the MST from the actuarial freedom from SVD, was 14.2 years (95% CI 11.7-18.3 years). Age at implantation, with a hazard ratio of 0.95 (95% CI 0.92-0.99), was the only significant risk factor affecting SVD. No differences were observed for gender, valve size, aetiology, atrial fibrillation, concomitant procedures or NYHA classification. Competing risk analysis including 3 distinct failures (non-valverelated death, valve-related-death and explantation attributable to SVD) was performed (Fig. 2) . At 20 years, the cumulative risk of valve explantation secondary to SVD was 44 ± 5%, lower than the corresponding actuarial estimate (75 ± 8%) and lower than the corresponding probability of death (49 ± 5%).
Effect of age on structural valve deterioration and reoperation. Figure 3 displays the Kaplan-Meier estimates of explantation due to SVD stratified by age groups (<55 years, 55-60 years and >60 years); the difference among groups was statistically significant (log-rank P = 0.013).
Evaluation of the cumulative risk of reoperation for SVD using age as the unique covariate was obtained from competing risk regression analysis and is presented in Fig. 4 . The corresponding hazard ratio was 0.94 (95% CI 0.91-0.96). Table 3 presents the number of years a patient could expect to be free from reoperation for SVD depending on age at implantation.
Finally, we subdivided our cohort by age quartiles and analysed the sample life expectancy and expected valve durability, in relation to the life expectancy of the general population in France (Fig. 5) . MVR reduced life expectancy compared with the general population in this young cohort; however, this difference declined as patient age at implantation increased. In 75% of patients (age at implantation >53 years), the expected valve durability estimate was equal to, or higher than, life expectancy after MVR.
GENERAL ADULT CARDIAC
Reoperation. Forty-nine reoperations were reported for a linearized rate of 3.9% per valve-years. Three mitral prostheses were explanted prophylactically during another cardiac operation. Forty-six reoperations were valve related: 44 due to SVD, 2 due to valve dehiscence and 1 due to operated valve endocarditis. Twenty-year actuarial freedom from valve explantation for all causes was 24 ± 7%.
DISCUSSION
When repairing a mitral valve is not possible, the question persists as to whether a biological or a mechanical prosthesis is preferable for MVR. A recent shift towards the use of bioprosthetic valves has occurred [1] . This evolution may be explained by improvements in the surgical outcomes of reoperations [11] , perceived improvements in the durability of newer generation bioprostheses [2, 3, 12] and the currently untested, yet highly anticipated, future use of percutaneous valve-in-valve technology to treat SVD [13] .
As the trend towards increased use of bioprostheses grows, the debate continues around the age limit for using a bioprosthetic valve versus mechanical valve in the mitral position. Age cut-offs are set at the point where the benefit of a bioprosthesis (no anticoagulation) outweighs the risk of reoperation for SVD. This highlights the need for long-term data, especially in younger patients.
In this study, we evaluated the long-term durability of the CE PERIMOUNT pericardial mitral bioprosthesis in patients aged 65 years or younger and reported a long-term follow-up, with a total of 1269 valve-years.
The main finding of this study is that the incidence of valverelated complications, in particular the incidence of SVD as defined by strict echocardiographic criteria, was lower than expected based on the available literature. Indeed, the expected valve durability calculated by the MST from the actuarial freedom from SVD was 14.2 years. Reoperation for SVD was a common outcome, but this was associated with low mortality. For example, a 60-year-old patient has a probability of 20% of needing a reoperation due to SVD after 11.9 years; the probability increases to 25% after 14.5 years. SVD: structural valve deterioration.
Figure 5:
Comparison of expected valve durability, life expectancy after MVR and relative life expectancy of the general population in France. The cohort was subdivided by age quartiles into 4 groups (mean age on the x-axis). MVR reduces life expectancy compared with the general population, although the difference declines with age at surgery. For 75% of the patients (age at implantation >53 years), the expected valve durability estimate is higher than the life expectancy after MVR. AUC: area under the curve; MST: median survival time; MVR: mitral valve replacement; SVD: structural valve deterioration.
Survival
We found that MVR reduced life expectancy in young patients compared with an age-and gender-matched population. However, this finding may not be specific to the use of a bioprosthesis. To date, only 2 randomized controlled studies have compared the outcomes between mechanical and bioprosthetic valves in the mitral position [14, 15] . Neither of these studies showed any difference in survival. However, they did not focus on a specific age subgroup.
Concerning younger patients, Chikwe et al. [16] recently reported that survival was unaffected by the choice of a mechanical or bioprosthetic mitral valve in patients aged 50-69 years matched by a propensity score. This suggests that the valve type does not influence long-term survival after MVR, even in young patients.
Thromboembolic events, bleeding and endocarditis
Recent retrospective studies have shown a similar incidence of thromboembolic events between mechanical and bioprosthetic valves [17, 18] . This study reported an actuarial freedom from thromboembolism of 93 ± 4% after 15 years, in accordance with the objective performance criteria recommended by the Food and Drug Administration (FDA).
More interestingly, our extended follow-up showed that 50% (22 of 44) of patients required warfarin in the very long term, mainly due to the new onset of atrial fibrillation or flutter. However, even when oral anticoagulation is needed, the target international normalized ratio is lower than with a mechanical valve, and vitamin K antagonists can be stopped in emergencies. Indeed, in this study, the rate of major bleeding (1.2% per valveyears; 20-year actuarial freedom 75 ± 12%) was lower than that observed in patients receiving mechanical prostheses [19, 20] . This could be explained by the different international normalized ratio goals: 2.5 for a bioprosthesis with atrial fibrillation, compared with 3 for a mechanical valve.
Moreover, we now have new non-vitamin K-dependent oral anticoagulants, which provide a more stable anticoagulation platform for patients. These result in the same reduction in thromboembolic risk as other anticoagulants but carry a lower risk of bleeding, particularly intracranial bleeding [21] .
Expected valve durability (structural valve deterioration, reoperation due to structural valve deterioration)
The major consideration with a deteriorated bioprosthesis, as stated by McGiffin et al. [22] , is 'the competing risks of death without re-replacement and re-replacement before death.' Jamieson et al. [23] reported a mortality rate of 6.3% for isolated mitral valve re-replacement. Only age at implantation and age at explantation were found to be significant risk factors for mortality. They concluded that the mortality rate after reoperation for SVD can be significantly reduced by optimizing the timing of surgery to before the onset of advanced symptoms and emergency status, advocating for a very strict echocardiographic follow-up.
It should be noted that the risk of reoperation is not limited to bioprosthetic valves; reoperation can also occur with mechanical valves, due to valve thrombosis or valve dehiscence. Chikwe et al.
[16] recently reported that the cumulative incidence of mitral valve reoperation at 15 years was 11% in the bioprosthesis group and 5% in the mechanical prosthesis group (hazard ratio 0.59; P = 0.03).
More recently, the limited early experience of transcatheter mitral valve-in-valve implantation in selected high-risk patients with deteriorated bioprostheses has been satisfying in general. Recently, Yoon et al. [13] reported early outcomes for 176 patients, with a technical success rate of 96%, only 2 procedurerelated deaths and 5.7% 30-day mortality. Although the future of this technique seems promising, the long-term outcomes and valve durability are still unknown, and larger series with longer follow-up are needed. Using the valve-in-valve technique as a reason for implanting bioprosthetic valves in younger patients obviously needs to be performed with caution.
Very few data on the long-term durability of mitral bioprostheses are available in the literature, especially for young patients. Intermediate outcomes of the pericardial Sorin Pericarbon prosthesis include a 12 year-freedom from SVD of 57 ± 7%: 86 ± 8% in patients older than 60 years and 37 ± 8% in younger patients [24] . The clinical performance of the Mitroflow pericardial bioprosthesis was even less satisfactory, with an 8-year freedom from SVD of 58 ± 6% [25] .
The durability of the CE PERIMOUNT bioprosthesis also compared favourably with the second-generation porcine valves [2, 4] . David et al. [12] reported that the 15-year actuarial and actual freedom from SVD with the Hancock II mitral porcine bioprosthesis was 66 ± 6% and 83 ± 3%, respectively. In patients younger than 65 years, the 15 year-actual freedom from SVD was 76 ± 5%.
Jamieson et al. [26] compared the second-generation CE supra-annular porcine valve with the CE PERIMOUNT bioprosthesis. They found that at 10 years, the freedom from SVD was lower for the CE supra-annular porcine valve: supra-annular porcine valve 65 ± 3% vs 84 ± 4% for the PERIMOUNT bioprosthesis in patients aged 60 years or younger, and 75 ± 4% vs 95 ± 2% for the PERIMOUNT bioprosthesis in patients aged 61-70 years. In particular, they emphasized the direct relationship between age at implantation and bioprosthetic valve durability. Comparing the durability of the CE PERIMOUNT pericardial versus porcine bioprostheses, Grunkemeier et al. reported rates of reoperation for SVD of 16 ± 3% at 15 years for porcine MVR vs 5 ± 3% at 8 years for pericardial valves (P = 0.13). Despite the shorter follow-up in the pericardial cohort, these authors concluded that a pericardial valve protected against reoperation for SVD in the mitral position (hazard ratio 0.39, P = 0.08) [27] . Patient age at valve implantation is a major determinant of life expectancy, risk of bleeding on anticoagulant treatment [28] and valve durability. Similar to other studies [2, 4, 12, 16, 25, 26] , we found a significant relationship between age at implantation and the risk of reoperation due to SVD.
When considering MVR, the choice between mechanical and bioprosthetic valves is often unclear. Patient age, the need for long-term anticoagulation and the existence of comorbidities are all important considerations when choosing the best valve for the individual patient. However, consensus guidelines have increasingly emphasized the patient's preference in preoperative decision-making [5, 6] . Quality of life is of paramount importance, especially for younger patients, and surveys indicate that many patients view the distant possibility of reoperation as a reasonable trade-off for freedom from lifelong anticoagulation, reduced quality of life and the poorer perceived health status associated with mechanical valves [29] .
